Poxel (OTCMKTS:PXXLF)‘s stock had its “buy” rating reissued by stock analysts at JMP Securities in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $21.00 target price on the stock. JMP Securities’ price objective suggests a potential upside of 213.43% from the company’s previous close.
Separately, Zacks Investment Research downgraded shares of Poxel from a “buy” rating to a “hold” rating in a research note on Thursday, August 19th.
Poxel stock opened at $6.70 on Friday. The business has a 50 day moving average of $6.87 and a 200-day moving average of $7.66. The company has a market capitalization of $161.40 million, a P/E ratio of -5.04 and a beta of 0.88. Poxel has a 1 year low of $6.47 and a 1 year high of $8.19. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.79 and a quick ratio of 2.79.
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles.
Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.